RxDoctor Payments Data

Jay Kaner, DO

Neurology · Clinton Township, MINPI 1316995384

Payments from drug & device makers

$27,815in general payments, 2019–2025

Across 1,442 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • EMD Serono, Inc.$4K
  • AbbVie$3K
  • Novartis$2K
  • UCB, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Biogen$1K
  • plus $14K from 54 others

What the payments were for

  • Speaking & faculty fees$2001%
  • Food & beverage$26,98297%
  • Education$6332%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
EMD Serono, Inc.140$3,569
AbbVie(2 entities)157$2,577
Novartis174$2,303
UCB, Inc.93$1,997
Teva Pharmaceuticals USA, Inc.98$1,525
Biogen51$1,400
Amgen(2 entities)101$1,147
Validus Pharmaceuticals LLC10$956
Lilly USA, LLC68$934
Pfizer57$829
Neurelis, Inc.33$702
Sanofi30$670
Neurocrine Biosciences, Inc.23$637
Harmony Biosciences LLC23$558
Amneal Pharmaceuticals LLC25$549
Argenx US, Inc.25$489
Lundbeck LLC21$468
Jazz Pharmaceuticals Inc.18$444
Avanir Pharmaceuticals, Inc.24$422
Takeda Pharmaceuticals U.S.A., Inc.15$418
Bristol Myers Squibb19$391
Eisai Inc.15$331
Genentech USA, Inc.16$329
Biohaven Pharmaceuticals, Inc.19$285
Supernus Pharmaceuticals, Inc.18$281
Acorda Therapeutics, Inc14$261
Otsuka America Pharmaceutical, Inc.10$248
Catalyst Pharmaceuticals, Inc.8$238
Acadia Pharmaceuticals Inc12$238
Johnson & Johnson7$207
Biohaven Pharmaceutical Holding Company Ltd.13$184
Corium, LLC10$174
MDD US Operations, LLC8$130
AstraZeneca6$128
Vertiflex, Inc.1$124
TG Therapeutics, Inc.3$119
Avadel CNS Pharmaceuticals, LLC5$102
Upsher-smith Laboratories LLC5$101
SK Life Science, Inc.4$98
Vanda Pharmaceuticals Inc.4$91
CSL Behring4$87
Tanabe Pharma America, Inc.3$86
Bausch Health US, LLC4$84
Greenwich Biosciences, Inc.1$78
Adamas Pharmaceuticals, Inc.6$78
Vertical Pharmaceuticals, LLC5$77
Mallinckrodt Enterprises LLC4$75
E.r. Squibb & Sons, L.L.C.3$64
Xeris Pharmaceuticals, Inc.3$58
Impel Pharmaceuticals Inc.2$57
Merz Pharmaceuticals, LLC2$54
GE HealthCare3$48
Promius Pharma LLC3$42
Banner Life Sciences, LLC2$40
Medtronic(2 entities)2$34
Ironshore Pharmaceuticals Inc.2$27
Sumitomo Pharma America, Inc.1$27
Grifols USA, LLC1$23
Sanofi-aventis U.S. LLC1$21
Hospira, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,815 in reported general payments places this provider in the 80th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$199,054
Medicare patients
398
Services billed
1,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5033$472,891
Kesimpta PenOfatumumab44$376,865
IngrezzaValbenazine Tosylate16$132,318
VumerityDiroximel Fumarate11$109,189
GocovriAmantadine Hcl22$109,014
AptiomEslicarbazepine Acetate50$71,724
InbrijaLevodopa11$67,071
RytaryCarbidopa/Levodopa23$60,802
GlatopaGlatiramer Acetate13$34,944
BriviactBrivaracetam23$33,848
XcopriCenobamate24$30,446
Emgality PenGalcanezumab-Gnlm36$27,734
EpidiolexCannabidiol (Cbd)15$26,022
Nurtec OdtRimegepant Sulfate22$24,902
Aimovig AutoinjectorErenumab-Aooe34$24,745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$637$132,31816 claims
BiogenVumerity$1,400$109,18911 claims
MDD US Operations, LLCGocovri$130$109,01422 claims
Acorda Therapeutics, IncInbrija$261$67,07111 claims
Amneal Pharmaceuticals LLCRytary$549$60,80223 claims
UCB, Inc.Briviact$1,997$33,84823 claims
PfizerNurtec Odt, Dilantin$829$31,68837 claims
SK Life Science, Inc.Xcopri$98$30,44624 claims
Corium, LLCAdlarity$174$6,33111 claims
Upsher-smith Laboratories LLCTopiramate$101$3,090219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 652 neurology providers in Michigan.

Other neurology in Clinton Township

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →